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Abstract
Objective: To report the experience gained over 4 years 
in working with the German SARI project (Surveillance of 
Antimicrobial Use and Antimicrobial Resistance in Intensive 
Care Units), and to compare SARI with data from the 
Swedish STRAMA and the US AUR surveillance system.
Methods: Prospective unit and laboratory based surveil-
lance was carried out in 40 German ICUs from 2001 
through 2004. WHO 2004 definitions of defined daily doses 
(DDD) per 1,000 patient days (pd) were used to express 
antimicrobial consumption (AD). Apart from the proportion 
of resistant isolates (RP), the incidence density of resistant 
isolates (RD) was calculated on the basis of the number of 
resistant isolates per 1,000 pd. To determine the changes 
over time, the Wilcoxon signed rank test for paired samples 
was used.
Results: From 1/2001 through 12/2004, 40 ICUs 
provided data on 53,399 isolates, a total of 789,569 DDD 
and 597,592 pd. Total AD ranged from 427 to 2,798, 
with the median being 1,351. There was no statisti-
cally significant change in total antimicrobial use, but 
a statistically significant decrease was observed in the 
use of aminoglycosides. RD was highest for MRSA with 
4.4 resistant isolates/1,000 pd followed by imipenem 
resistant Pseudomonas aeruginosa with 1.7 resistant 
isolates/1,000 pd. The corresponding RPs were 21.5% and 
23.2%. Over the 4-year period (2001–2004), significant 
increases were seen in the RDs of third generation cepha-
losporin and ciprofloxacin resistant Escherichia coli. In 
2004, the mean RD reached 0.28 and 1.41, respectively. 
In comparison, the RP of selected pathogens was highest 
in the US ICUs and lowest in Swedish ICUs, with the 
exception of imipenem resistant P. aeruginosa.
Conclusion: Antibiotic consumption remained stable over 
a period of 4 years, (the mean being 1,321 DDD/1,000 pd). 
The same applied to the situation regarding resistance in 
Staphylococcus aureus, enterococci and P. aeruginosa. For 
most pathogens the RP was higher in SARI ICUs than in 
Swedish ICUs, but lower than in US ICUs.
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Introduction
Antimicrobial use is the key driver of resistance, either 
because it selects a resistant mutant, or because it allows 
the emergence of a resistant pathogen in colonisation flora 
[1, 2]. In many countries, the high frequency of resistant 
bacterial pathogens presents a major public health prob-
lem. Moreover, such resistance is slow to reverse or may 
even be irreversible, and the therapeutic options are there-
fore reduced [3]. 
In order to influence the spread of resistant pathogens 
and develop sustainable systems, the European Commis-
sion and the World Health Assembly (WHA) Resolution 
therefore encourage the appropriate and cost-effective 
use of antimicrobials. It is also necessary to detect resis-
tant pathogens and to monitor antimicrobial consumption 
volumes, their patterns of use and the impact of infection 
control measures [4, 5]. 
However, the relationship between antibiotic use and 
the emergence of resistance is complex. The type of mi-
cro-organism, the resistance mechanisms involved and the 
relative importance of the different epidemiological vari-
ables will determine the likelihood of an intervention be-
ing successful. Until these interactions are fully explored, it 
seems reasonable to promote the prudent use of antibiotics 
as the single most important measure to stop increases in 
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resistance trends. Comparison of data as a benchmarking 
instrument is an important initial step, and serves to help 
ICUs recognize problems and improve the way in which 
antimicrobials are used [6].
In Europe, the Swedish STRAMA project (ICU sec-
tion of the Swedish Strategic Programme for the Rational 
Use of Antimicrobial Agents and Surveillance of Resis-
tance, http://www.strama.org) and the German SARI proj-
ect (Surveillance of Antimicrobial Use and Antimicrobial 
Resistance in Intensive Care Units, http://www.sari-antibi-
otika.de) are Government sponsored. The main objective 
of these two surveillance systems is to provide information 
on the use of antimicrobials in risk areas such as ICUs, 
and to supply data on the incidence percentages of resis-
tant bacterial pathogens [7–10]. In the US, this was done 
earlier in project ICARE (Intensive Care Antimicrobial 
Resistance Epidemiology), which has now been succeeded 
by AUR (Antimicrobial Use and Resistance) [11, 12].
This paper presents data from SARI over a period of 
4 years and compares them with data from other ICU sur-
veillance systems, i.e. STRAMA and AUR.
Methods
SARI was initiated in February 2000 with the objective of col-
lecting monthly prospective data from SARI-ICUs actively par-
ticipating in the German hospital infection surveillance system 
(KISS) [13]. In our analysis, we concentrated on the period 2001 
through 2004, because in 2000 the data set only covered 16 ICUs. 
From 1/2001 through 12/2004, 40 ICUs provided data and were in-
cluded in the analysis. The 40 ICUs were located in 24 geographi-
cally distinct hospitals. Of this number, 15 belonged to university 
hospitals. Fourteen ICUs were interdisciplinary, 15 were surgical 
and 11 were medical. ICU bed numbers ranged from 6 to 26, with 
a median of 12. 
A report comparing local monitoring data for each ICU and 
SARI benchmark data (i.e. aggregate summary data on all SARI 
ICUs) was initially presented to each ICU every 3 months. Since 
2004, this report has been compiled every 6 months. In addition, 
a 2-day workshop took place once a year. Monthly antimicrobial 
usage data were obtained from computerised hospital databases. 
Consumption was expressed as defined daily doses (DDD) and 
normalised per 1,000 patient-days (AD = antimicrobial usage 
density), 1 DDD being the standard adult daily dose of an anti-
microbial agent for 1 day’s treatment defined by the WHO (data 
are recalculated by DDD index 2004) [14]. 
The ICUs indicated the number of isolates tested per month 
belonging to the following sentinel bacterial species: Staphylococ-
cus aureus, coagulase negative staphylococci (CNS), Enterococcus 
faecalis, Enterococcus faecium, Pseudomonas aeruginosa, Entero-
bacter cloacae, Citrobacter spp., Serratia marcescens, Acinetobater 
baumannii, Stenotrophomonas maltophilia, Streptococcus pneu-
moniae, Escherichia coli and Klebsiella pneumoniae; furthermore, 
on the number of isolates tested against sentinel antibiotics and 
the number of isolates resistant to these antibiotics. They were 
specified as resistant by the participating ICUs using the identifi-
cation method routinely employed in their clinical laboratory. The 
data were presented using interpretive criteria recommended by 
the German Industrial standard (DIN) or the National Commit-
tee for Clinical Laboratory Standards (NCCLS) [15, 16]. Calcu-
lation was done irrespective of the interpretive criteria applied. 
To exclude copy strains, all the laboratories were obliged to use 
the same protocol. A copy strain was defined as an isolate of the 
same species showing the same susceptibility pattern throughout 
the period of 1 month in the same patient, regardless of the site 
of isolation. 
Data on hospital and patient characteristics were obtained 
from the KISS system, i.e. type of hospital, number of ICU beds, 
type of ICU (medical, surgical, interdisciplinary), number of pa-
tient-days, number of device days and mean length of stay. The 
ICUs collected data on nosocomial infections (NI) for each pa-
tient according to the definitions given by the Centers for Disease 
Control and Prevention (CDC) [13]. 
The proportion of resistant isolates was calculated by divid-
ing the number of resistant isolates by the total number of isolates 
belonging to the species tested against this antibiotic, multiplied 
by 100 (RP). The incidence density of resistant isolates was de-
fined as being the number of resistant isolates per 1,000 patient 
days (pd) (RD).
For analysis of temporal changes in resistance densities and 
antimicrobial consumption, we included all the SARI-ICUs that 
had provided data in 2001, 2002, 2003 and 2004. We then com-
pared the data provided by the individual ICUs in the year 2001 
with that of the same ICU in 2004 (n = 34). Additionally, in the 
analysis of temporal changes in RD we included only those ICUs 
that had provided at least ten isolates per antimicrobial/pathogen 
per year for testing, because RDs are statistically unsafe if the 
number of isolates tested is insufficient. To determine the changes 
between the two terminal years (year 2001 vs year 2004), we chose 
the Wilcoxon signed rank test for paired samples as described 
by Fridkin et al. [17]. The statistics are based on the ranking of 
absolute values of differences. Pairs with large differences have 
greater weight than pairs with small differences. 
To test for differences in RD in selected pathogens according 
to the type of ICU (medical, surgical, interdisciplinary), hospital 
size (> 600 beds) and university status, Kruskal-Wallis and Wil-
coxon tests for independent samples were employed.
Statistical analyses were performed using SAS version 8.01 
and EpiInfo version 6.04.
Results
A total of 789,569 DDD and 597,592 pd were included in 
the analysis. Table 1 shows pooled antibiotic consumption 
in accordance with the WHO classification over a period of 
4 years for all 40 SARI ICUs by ICU type. The total anti-
microbial ADs ranged from 427 to 2,798, with a median of 
1,351 and a mean of 1,321. They did not differ significantly 
by type of ICU, size of hospital (> 600 beds) or university 
status. Penicillins with ß-lactamase inhibitor were the an-
timicrobial group with the highest AD in all types of ICU. 
In medical ICUs, these were followed by quinolones, peni-
cillins with extended spectrum and macrolides, in surgical 
ICUs by quinolones and carbapenems and in interdisciplin-
ary ICUs by second generation cephalosporins and quino-
lones. There was no statistically significant change in total 
antimicrobial use from 2001 through 2004, but statistically 
significant changes were found in the antimicrobial classes 
used. The median administration of extended spectrum 
penicillins increased from 75.3 to 102.3 (mainly due to the 
use of piperacillin); the administration of penicillins with 
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ß-lactamase inhibitor combinations decreased 
from 258.5 to 191.5 (mainly due to a decrease 
in the use of piperacillin-tazobactam) and the 
administration of aminoglycosides also dropped 
from 59.6 to 28.4). 
The laboratory data covered 53,399 isolates 
(29,160 gram positives and 24,239 gram negatives). 
The number of SARI-isolates i.e. the 13 sentinel 
microorganisms per 1,000 pd ranged from 17.3 to 
164.6, with the median lying at 80.0. The number 
of annual SARI-isolates ranged from 33 to 1199, 
with the median being 316. RD and RP did not 
differ significantly in university and non-univer-
sity ICUs or by type of ICU. However, in ICUs 
located in hospitals with more than 600 beds the 
RD and RP of imipenem resistant P. aeruginosa 
were significantly higher than smaller hospital 
ICUs (p = 0.046 and 0.043, respectively).
A comparison of the median length of stay 
revealed that between 2001 and 2004 the length 
of stay increased in 15 and decreased in 20 ICUs; 
however, this was not statistically significant (me-
dian length of stay in 34 ICUs – 4.2 in 2001 and 3.8 
in 2004). From 2001 through 2004, mean device-
associated nosocomial infection rates, expressed 
as NI/1,000 device days were as follows: urinary 
tract infections 3.1 (range 0.3–8.3), blood stream 
infections 1.8 (range 0.2–4.6), and pneumonia 6.8 
(range 2.0–17.3). The use of invasive devices did 
not change significantly over time (2001 vs 2004). 
With respect to resistance, pooled data over 
4 years showed the highest mean RD of 4.4 resis-
tant isolates per 1,000 pd for MRSA i.e. methi-
cillin resistant S. aureus (mean resistance pro-
portion 21.5%) followed by imipenem resistant 
P. aeruginosa with an RD of 1.7 and a mean 
RP of 23.2% (Table 2). Furthermore, data sets 
on RD from the year 2001 were compared with 
those of the year 2004. Significant increases were 
found for the RD of third generation resistant 
E. coli (over 4 years 14 ICUs showed an increase 
and only 6 ICUs a decrease in RP), as well as for 
the RD of ciprofloxacin resistant E. coli (20 ICUs 
showed an increase and only 5 ICUs a decrease) 
(Table 2). Figure 1 shows the pooled mean RD 
for January through December 2004 for selected 
antimicrobial-resistant pathogens. Next to or 
overlapping this point is the 95% confidence 
interval of mean RD over the previous 3 years 
(2001–2003). The most dramatic increase in 
mean RD was observed for vancomycin resistant 
E. faecium (354%), followed by third generation 
resistant E. coli (47%), ciprofloxacin resistant 
E. coli (21%) and ceftazidime resistant P. aeru-
ginosa (6%). In contrast, vancomycin resistant 
E. faecalis decreased by 100% and third genera-
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tion resistant K. pneumoniae by 34%. At –2%, MRSA 
remained fairly stable.
For comparison with the US-American and the Swed-
ish surveillance systems, RP were compared with the 
latest available data, showing that with the exception of 
imipenem resistant P. aeruginosa the RP were highest in 
US-ICUs (Figure 2).
Discussion
This study reports the data gained over 4 years of work-
ing with SARI, an ongoing surveillance system for antibi-
otic use and resistance. We discuss the principal findings: 
(1) In SARI ICUs the mean antibiotic consumption was 
1,321 DDD/1,000 pd, and the preferred antibiotic groups 
were penicillins with beta-lactamase inhibitors and quino-
lones. (2) Total antibiotic consumption remained stable 
over 4 years. (3) Resistance densities for third generation 
cephalosporin and ciprofloxacin resistant E. coli rose sig-
nificantly over 4 years. Otherwise, the resistance situation 
remained stable. (4) The RP of selected pathogens was 
highest in the US ICUs and lowest in Swedish ICUs, with 
the exception of imipenem resistant P. aeruginosa.
In the hospitals, antimicrobial use 
ranged from 427 to 2,798 DDD/1,000 pd. 
This heterogeneity was also seen in 29 
Swedish ICUs, where antibiotic con-
sumption ranged from 605 to 2,143 DDD/
1,000 pd, with a median of 1,147 between 
1999 and 2000 [7]. It is a well-known 
fact that antibiotic consumption in ICUs 
is generally higher than hospital-wide 
consumption [18]. The preferred anti-
biotic groups in all SARI  ICUs were 
penicillins with beta-lactamaseinhibitors 
(AD = 277) quinolones (AD = 141) and 
second generation cephalosporins (AD 
118). In Swedish ICUs, cephalosporins 
(AD = 287)  and  isoxazolyl  penicillin 
(AD = 156) outranged other classes of 
antimicrobials [7, 9]. 
Over the 4-year period, we saw a 
significant decrease in the use of amino-
glycosides (26 out of 34 ICUs decreased 
use) and of penicillins with beta-lac-
tamase inhibitors. However, the latter 
was due to the replacement of the fixed 
combination piperacillin/tazobactam by 
the individual compounds piperacillin 
and sulbactam, which are less expensive 
in Germany. There was no change over 
time in the total use of antibiotics within 
individual ICUs. 
Summarized data are presented both 
as RD as an indirect parameter of the bur-
den of resistance, i.e. resistant isolates/
1,000 pd as described by Schwaber et al. 
[19, 20] and as RP. We used RD only for all the remaining 
analyses. The pitfall of RP, which is widely used and is easy 
to interpret, is that the number of resistant bacterial isolates 
depends on the number of susceptible isolates. If the num-
ber of susceptible isolates varies or changes over time, e.g. if 
some laboratories report contaminants, while others do not, 
or if screening procedures are introduced, these measures 
will all affect the RP. However, the resistance density only 
depends on the number of resistant isolates. 
MRSA is by far the most resistant isolate with the 
highest burden of resistance (4.4 MRSA/1,000 pd), im-
plying higher costs for isolation, decolonisation and the 
treatment of infections. Looking at changes over time 
in individual ICUs we saw no significant change in the 
RD of MRSA. The fact that the RD of MRSA increased 
in 18 and decreased in 12 ICUs might reflect the impact 
of different efforts undertaken by individual ICUs both 
with regard to infection control and antibiotic manage-
ment. Especially the consumption of quinolones can have 
a significant impact on the MRSA resistance situation 
[21, 22]. A stable MRSA situation and a significant 
increase in third generation cephalosporin and ciprofloxacin 
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5
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Figure 1. Comparison of pooled mean resistance densities (RD) of all SARI  ICUs 
for selected antimicrobial-resistance pathogens from 1/2004 to 12/2004 with 
1/2001–12/2003;    =2004 pooled mean RD;    = 2001–2003 95% confidence 
interval of mean RD.
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resistant E. coli (2001–2004) confirm findings and trends 
seen earlier over a period of 3 years in SARI  ICUs and 
described for MRSA in detail elsewhere  [23, 24]. Com-
parison of the mean RD in 2004 with the mean RD in the 
years 2001 through 2003 showed a dramatic increase in 
the percentage of vancomycin resistant E. faecium. How-
ever, the increase in vancomycin resistant E. faecium was 
due to an outbreak in hospitals in South-West Germany 
(only two of the SARI ICUs were affected) and is a good 
example of the need to exercise care in the interpretation 
of pooled data [25]. 
Comparison of US-AUR data (2003) with German 
SARI data (2004) and Swedish STRAMA data (1999–
2000) showed that resistance proportions for selected 
pathogens were highest in the US ICUs and lowest in 
Swedish ICUs [11]. However, interestingly, at 30%, resis-
tance in P. aeruginosa to imipenem was highest in Swed-
ish ICUs compared with 23.8% in German ICUs and 
21.1% in US-American ICUs [7]. This might be due to the 
fact that while carbapenem consumption was 37.8 DDD/
1,000 pd in interdisciplinary US AUR-ICUs and 84.1 in 
German SARI ICUs, it was 113 in Swedish STRAMA 
ICUs. The striking differences in prescribing preferences 
between one country and another should be taken into 
consideration and might be crucial for the success of pos-
sible interventions.
Thus, a Hawthorne effect, as described for nosoco-
mial infection rates, i.e. reduction by observation alone, 
was not observed in either AUR or SARI. The 354% 
increase in vancomycin resistant E. faecium observed 
by SARI was caused by the regional outbreak, and 
ciprofloxacin resistant 
E. coli increased without an 
increase in quinolone ICU-
consumption. Especially 
in the case of quinolones, 
hospital-wide and ambula-
tory care consumption in-
fluences the development 
of resistance. MacDougall 
et al. found that for quino-
lone resistant E. coli, total 
community quinolone use 
within a 16 km radius cor-
related significantly with 
resistance in the hospitals 
[26]. Therefore, campaigns 
for the appropriate use of 
antibiotics should ideally 
focus not only on ICUs, 
but on all those physicians 
prescribing them.
This study has some 
limitations. Selection 
bias cannot be excluded 
because participation in 
SARI was voluntary and ICUs encountering higher resis-
tance rates would obviously be aware of the problem and 
wish to take part. Bias due to inclusion of all isolates must 
be taken into account, especially with respect to screening 
policies and outbreaks. In Germany, ICUs perform suscep-
tibility testing in accordance either with NCCLS or DIN. 
Like other surveillance systems we did not differentiate be-
tween the methods used, which should be considered in the 
data analysis [27]. As data are laboratory and unit-based, 
they are prone to ecologic fallacy, i.e. improper inference 
about individual-level associations based on associations 
measured only at the aggregate level. 
In conclusion, antibiotic consumption remained stable 
over a period of 4 years with a mean value of 1,321 DDD/
1,000  pd. The burden of resistance in S. aureus and 
P. aeruginosa also remained stable, whereas resistance in 
third generation cephalosporin and ciprofloxacin resistant 
E. coli increased. The striking differences in the resistance 
situation and in antibiotic prescribing practices in different 
countries underline the need for national or even locally 
adapted guidelines on empiric antibiotic therapy. Further 
analysis of these differences will help improve the way in 
which antimicrobials are used in countries whose resistance 
situation is better than in others.
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